1 July 2025 in Circulation: Arrhythmia and Electrophysiology
FCfor the Cardiac Sarcoidosis Consortium
for the Cardiac Sarcoidosis Consortium
+33
BACKGROUND: Differences in cardiac sarcoidosis between racial groups remain understudied. Therefore, this study aims to explore race differences in patients with cardiac sarcoidosis. METHODS: We analyzed data from the Cardiac Sarcoidosis Consortium, an international registry including over 25 centers. The primary clinical outcome was a composite end point of all-cause mortality, left ventricular assist device implantation, heart transplantation, or implantable cardioverter defibrillator therapy. RESULTS: A total of 619 patients were included in the study (362 White, 193 Black, and 64 other races). Black patients were diagnosed with cardiac sarcoidosis at a younger age (50.5±11.8 versus 53.7±10.5 years old; P =0.010) compared with White patients. Left ventricular ejection fraction was significantly lower in Black patients (44.6±15.4 versus 48.3±14.0; P =0.008). In addition, extracardiac involvement in the lungs (80.3% versus 72.7%; P =0.046), skin (22.8% versus 12.4%; p =0.002), and eyes (13.5% versus 5.5%; P =0.001) was more prevalent in Black patients. Patients had significantly higher rates of hypertension (69.9% versus 50.6%; P <0.001), diabetes (37.8% versus 21.0%; P <0.001), smoking (40.9% versus 26.8%; P <0.001), chronic obstructive pulmonary disease or emphysema (15.5% versus 4.1%; P <0.001), and chronic kidney disease (25.9% versus 12.4%; P 35% group (24.1% in Black versus 25.9% in White; P =0.72) and the left ventricular ejection fraction ≤35% group (51% versus 42.5%; P =0.35). CONCLUSIONS: Black patients with cardiac sarcoidosis exhibited significantly higher rates of lung, skin, and eye involvement and comorbidities, but had similar cardiac clinical outcomes and all-cause mortality compared with White patients. Nonetheless, ascertainment bias cannot be excluded.
1 May 2005 in Heart Rhythm
20 June 2017 in EP Europace
Background: Transcatheter aortic valve replacement (TAVR) can lead to atrioventricular (AV) conduction changes and need for permanent pacemaker (PPM) implantation. There is currently no consensus on clinical decision making for PPM evaluation in patients undergoing TAVR.
1 August 2018 in European Heart Journal
SIS-ICD IDE Study Investigators
S-ICD IDE Study Investigators
+10
Background: The Subcutaneous (SQ) Implantable Cardioverter Defibrillator (ICD) requires defibrillation testing at the time of implantation. Predictors of defibrillation success based upon the anterior and posterior position of the pulse generator have been identified through computer modeling.